Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine

Abstract

An uncontrolled retrospective study was conducted looking at the use of oral controlled-release hydromorphone in palliative care patients. Over a 2-year period 55 patients were switched to hydromorphone therapy, and the efficacy and outcomes were assessed. Urea and electrolyte measurements were also recorded at the time of opioid switch and renal impairment defined as urea > 10.5 mmol/l and/or creatinine [.greaterequal] 101 mmol/l. This group of 29 patients with abnormal urea and/or creatinine (Group 1) was compared with the remaining 26 patients (Group 2) who had normal urea and creatinine.

The major reasons for change to hydromorphone were side-effects (cognitive/ drowsiness/nausea) on previous therapy. Following a switch to hydromorphone these side-effects improved in over 80% of patients (n = 55). Comparison between Group 1 and 2 demonstrated a significant difference in renal function but no significant differences in reasons for change, dose of opioids or response to change (over 80% improvement following opioid switch).

We conclude that hydromorphone is a flexible second-line alternative to morphine that is particularly useful when intolerable side-effects are experienced with other opioids. In renal impairment (including two patients with end-stage renal failure) we found hydromorphone to be safe and effective. Further clinical and pharmacokinetic studies are required.

Keywords

hydromorphone metabolites renal impairment palliative care side effects

Get full access to this article

View all access options for this article.

References

Report of WHO Expert Committee . Cancer pain and palliative care. World Health Organ Techn Rep Ser 1990; 804: 24.

Hays H , Hagen N , Thirlwell M et al. Comparative clinical efficacy of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 1994; 74: 1808–1816.

de Stoutz ND , Bruera E , Suarez-Alamazor M . Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378–384.

Twycross R , Wilcock A , Thorp S . Palliative care formulary. Oxford: Radcliffe Medical Press, 1998: 119.

Babul N , Darke AC , Hagen N . Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995; 10: 184–186.

Cone EJ , Phelps BA , Gorodetzky CW . Urinary excretion of hydromorphone and metabolites in humans, rats, dogs, guinea pigs, and rabbits. J Pharm Sci 1977; 66: 1709–1713.

Data from Napp Laboratories.

Hagen N , Thirlwell MP , Dhaliwal HS , Babul N , Harsanyi Z , Darke AC . Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 1995; 35: 37–44.

Wright WE , Nocente ML , Smith MT . Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation. Life Sci 1998; 63: 401–411.

10.

Eisele JH , Ggrigsby EJ , Dea G . Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992; 49: 231–232.

11.

Hagen N , Swanson R . Multifocal myoclonus and seizures in extremely high-dose opioid administration. Proc Am Acad Neurol 1993; 43: A400.

12.

Babul N , Darke AC . Putative role of hydromorphone metabolites in myoclonus. Pain 1992; 51: 260–261.

13.

Galer BS , Coyle N , Pasternak GW , Portenoy RK . Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87–91.

14.

Ivarson M , Neil A . Differences in efficacy between morphine and methadone demonstrated in the guinea pig ileum. Pharmacol Toxicol 1989; 65: 368–371.

15.

Jang Y , Yoburn BC . Evaluation of receptor mechanisms mediating fentanyl analgesia and toxicity. Eur J Pharmacol 1991; 197: 135–141.

16.

ABPI Compendium of data sheets and summaries of product characteristics. London, Datapharm Publication, 1998–1999: 782.

17.

Lawlor P , Turner K , Hanson J , Bruera E . Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997; 72: 79–85.

18.

Bruera E , Periera J , Watanabe S , Belzile M , Kuehn N , Hanson J . Opioid rotation in patients with cancer pain. Cancer 1996; 78: 852–858.

19.

Davies G , Kingswood C , Street M . Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31: 410–422.

20.

Guay DRP , Awni WM , Findlay JWA et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988;43: 63–71.

21.

Sear JW , Hand CW , Moore RA , McQuay HJ . Studies on morphine disposition: Influence of renal failure on the kinetics of morphine and its metabolites. Br J Anaesth 1989; 62: 28–32.

22.

Kirvela M , Lindgren L , Seppala T , Olkkola KT . The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantations. J Clin Anesth 1996; 8: 13–18.

23.

Osbourne RJ , Joel SP , Slevin ML . Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J 1986; 292: 1548–1549.

24.

Hagen NA , Foley KM , Cerbone DJ , Portenoy RK ; Inturrisi CE . Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 1991; 6: 125–128.

25.

Morrison RBI , Davison JM , Kerr DNS . Clinical physiology of the kidney: Tests of renal function and structure. In: Weatherall DJ , Ledingham JGG , Warrell DA eds. Oxford textbook of medicine. Oxford: Oxford University Press, 1988: 18.5–18.6.

26.

Quan A , Adams R , Ekmark E , Baum M . Serum creatinine is a poor marker of glomerular filtration rate in patients with spina bifida. Dev Med Child Neurol 1997; 39: 808–810.

27.

Lindegaard MW , Aass N , Bue ES , Theodorsen L , Fossa SD . Glomerular filtration rate, 131I-hippuran clearance and estimated creatinine clearance in cancer patients. Br J Cancer 1991; 64: 401–405.

28.

Gaspari F , Perico N , Remuzzi G . Measurement of the glomerular filtration rate. Kidney Int 1997; 52: S-151–S-154.